Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $6.29 and last traded at $5.72, with a volume of 5108700 shares. The stock had previously closed at $5.72.
A number of equities analysts have recently issued reports on the company. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday. B. Riley started coverage on Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price objective for the company. Cantor Fitzgerald set a $2.00 target price on Arrowhead Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, December 12th. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Finally, Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 target price for the company in a report on Monday, November 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $3.13.
The company has a market capitalization of $470.67, a price-to-earnings ratio of -13.38 and a beta of 1.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 1st. The stock was sold at an average price of $3.69, for a total value of $73,800.00. Following the completion of the sale, the chief operating officer now directly owns 948,356 shares in the company, valued at $3,499,433.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.57% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. ING Groep NV acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $3,500,000. Allianz Asset Management GmbH acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $1,958,000. Schwab Charles Investment Management Inc. grew its stake in Arrowhead Pharmaceuticals by 8.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock valued at $686,000 after acquiring an additional 15,132 shares during the period. Virtu KCG Holdings LLC grew its stake in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 53,215 shares during the period. Finally, Acadian Asset Management LLC grew its stake in Arrowhead Pharmaceuticals by 1,177.7% in the fourth quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 66,055 shares during the period. 20.05% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/19/arrowhead-pharmaceuticals-arwr-sets-new-12-month-high-at-6-29.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.